Current methods for assessing ambulatory function in patients with Duchenne muscular dystrophy do not fully reflect how they experience DMD in their daily lives. Now, researchers have developed a new endpoint measured by a wearable device that records a patient's fastest spontaneous strides outside the clinic. What's more, it could become the first-ever digital primary endpoint approved by regulators.
